
A substantial proportion of children living with HIV worldwide continue to lag behind adults in diagnosis, treatment access, and viral suppression, underscoring persistent gaps in pediatric HIV care. Although many pregnant women receive antiretroviral therapy to prevent transmission and a majority of exposed infants are tested early, prompt diagnosis and immediate treatment initiation in infancy are critical, as early therapy significantly reduces mortality. In resource‑limited settings, dried blood spots (DBS) provide a practical solution by simplifying specimen collection, storage, and transport from remote areas to centralized laboratories. In this study, we evaluated the analytical and clinical performance of the Alinity m HIV‑1 assay, a real‑time PCR test that supports DBS for qualitative early infant diagnosis (EID). The assay demonstrated a limit of detection (LOD) of 392.68 copies/mL, reproducibility at 2.60, 3.60, 5.00, and 7.30 Log copies/mL with total standard deviation ≤1.00 cycles, and sample stability with 100% detection after up to 12 weeks of storage from −20 °C to 31 °C with minimal cycle number variation at 3x and 10x LOD. Clinical evaluation of 391 specimens showed 100% agreement with the comparator assay, with cycle number correlation coefficient (r) of 0.905 for cycle numbers ranging from 19.42 to 36.90. Overall, these results demonstrate the utility of the Alinity m DBS EID HIV-1 assay for use in early infant diagnosis of HIV-1.
Somalia has not detected wild poliovirus since 2014, yet persistent transmission of circulating vaccine-derived poliovirus type 2 (cVDPV2) since 2017—with 39 confirmed cases across 14 regions as of March 2024 and international spread to Ethiopia and Kenya—underscores a critical "surveillance-to-action gap." Detection through acute flaccid paralysis and environmental surveillance does not reliably translate into effective response. In conflict-affected zones, an estimated 500,000 children under five remain unreachable for vaccination, with 95% of zero-dose children from the South Central region and 60% residing in inaccessible districts. Novel diagnostic tools, including a multiplex poliovirus type 2-specific real-time quantitative PCR assay with 98.3% specificity, enable rapid detection of cVDPV2 RNA in wastewater and stool samples, potentially transforming environmental surveillance into a real-time early warning system. However, laboratory advances must be complemented by community engagement; programs have successfully traced and vaccinated over 39,000 zero dose and defaulter children through local leadership networks. Somalia's polio strategy must evolve from passive detection to an integrated surveillance-for-action system. Priorities include deploying rapid molecular diagnostics, linking detections to district level micro plans targeting zero-dose children, expanding community-based surveillance to inaccessible areas, and strengthening cross-border coordination. Without this decisive shift, cVDPV2 will continue to circulate silently among vulnerable children and threaten regional eradication gains.
Background Laboratory biomarkers that predict progression from mild COVID-19 to hospitalization are not well defined. Objective To evaluate the performance of C-reactive protein (CRP) and plasma SARS-CoV-2 RNA for predicting hospitalization among mild COVID-19 outpatients enrolled in a randomized controlled trial of COVID-19 convalescent plasma (CCP). Methods CRP and plasma SARS-CoV-2 RNA were measured in 487 outpatient trial participants screened before March 2021. Weighted analyses accounting for sampling probabilities were used to estimate positive predictive values (PPVs) and sensitivities for progression to hospitalization, with performance compared across trial arms. Results Elevated CRP (>1 mg/dL) was present in 27% (131/487) of participants, and plasma SARS-CoV-2 RNA was detectable in 15% (74/487). In weighted analyses, PPVs for hospitalization were 15% (95% CI, 10–21) for elevated CRP alone, 25% (95% CI, 16–35) for detectable plasma RNA alone, and 37% (95% CI, 23–52) when both biomarkers were present. Among participants with elevated CRP and plasma RNA >500 copies/mL, PPV increased to 72% (95% CI, 37–100). Elevated CRP demonstrated 100% sensitivity for hospitalization in CCP-transfused participants and 54% in control plasma–transfused participants, while detectable plasma RNA demonstrated sensitivities of 60% and 50%, respectively. Among individuals meeting severe COVID-19 risk criteria based on sex, age, obesity, or comorbidities, the combination of normal CRP and undetectable plasma RNA have a high negative predictive value for hospital progression risk. Conclusions The combination of elevated CRP and detectable plasma SARS-CoV-2 RNA improves laboratory-based risk stratification for progression to hospitalization among outpatients with mild COVID-19.
To prospectively evaluate the diagnostic performance of the Quick Chaser SARS-CoV-2 rapid antigen assay in symptomatic children using reverse transcription polymerase chain reaction (RT-PCR) as the reference standard and identify factors associated with discordant antigen results. We conducted a prospective observational study of symptomatic children who underwent paired antigen testing and RT-PCR using the same nasopharyngeal specimen between September and December 2022. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall agreement were assessed. Cycle threshold (Ct) values, SARS-CoV-2 RNA viral loads, symptom duration, and clinical characteristics were compared between RT-PCR-positive children with positive and negative antigen results. Among 229 children, 63 (27.5%) were RT-PCR positive. The assay demonstrated a sensitivity of 87.3% (95% confidence interval [CI], 76.5–94.4%), specificity of 99.4% (95% CI, 96.7–100.0%), PPV of 98.2% (95% CI, 90.4–100.0%), NPV of 95.4% (95% CI, 91.1–97.8%), and overall agreement of 96.1% (95% CI, 92.7–98.2%). False-negative antigen results were associated with higher Ct values, lower viral loads, and testing on the day of symptom onset. Antigen positivity declined with increasing Ct values and decreasing viral loads and was significantly lower on the day of symptom onset than on Days 1–2. The Quick Chaser SARS-CoV-2 assay demonstrated high diagnostic accuracy in symptomatic children. False-negative results were more frequent in specimens with low viral burden and when testing was performed on the day of symptom onset. These findings may improve interpretation of negative antigen results in pediatric practice.